Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitax
A phase 2 trial of Olaparib, Paclitaxel / nab-paclitaxel, Carboplatin in ovarian cancer, run by AstraZeneca, active and no longer recruiting.
Overview
Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer is a phase 2 interventional study registered as NCT01081951 by AstraZeneca, with 162 participants enrolled, started 2010-02-04 and due to reach its primary completion in 2011-10-10. Interventions recorded: olaparib, paclitaxel, carboplatin, paclitaxel, Drug: carboplatin. Conditions listed: Ovarian Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
Shares Olaparib, AstraZeneca, Ovarian cancer.
- TrialD9319C00001- 1L OC Mono Global RCT
Shares Olaparib, AstraZeneca, Ovarian cancer.
- TrialCATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ov
Shares Paclitaxel / nab-paclitaxel, Carboplatin, Ovarian cancer.
- TrialOlaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Shares Olaparib, AstraZeneca, Ovarian cancer.
- TrialPhase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Pat
Shares Olaparib, Paclitaxel / nab-paclitaxel, Carboplatin, Ovarian cancer.
- TrialStudy of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)
Shares Olaparib, Paclitaxel / nab-paclitaxel, AstraZeneca, Carboplatin.
- TrialA Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN1
Shares Olaparib, Carboplatin, Ovarian cancer.
- TrialA Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.